REG - Yourgene Health PLC - Appointment of Director

Yourgene HealthAnnouncement

29/07/2019 07:05

RNS Number : 9441G
Yourgene Health PLC
29 July 2019
 


Yourgene Health plc
("Yourgene", the "Company" or the "Group")
 
Appointment of Director
 
Manchester, UK - 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect.  Dr Brown will act as the Senior Independent Director on the Board.
 
Dr Brown has over 20 years' capital markets experience in the healthcare and life sciences sector. He is currently a Senior Independent Director of BioCity and Acacia Pharma and is Chairman of Cell Therapy Catapult and Synpromics. Additionally, he has previous significant board experience with roles including Chairman of Axis-Shield, Chairman of BTG, Non-executive Director of Vectura and Chief Executive Officer of Acambis.
 
Further disclosures on Dr Brown as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are included in the appendix below.
 
Adam Reynolds, Chairman of Yourgene, commented: "We are delighted to welcome John to the Board of Yourgene. John has unrivalled experience in working with publicly listed life sciences businesses and we look forward to drawing on his experience as we drive awareness of Yourgene's expanded product portfolio across our target markets. John's skillset and experience is a great strategic fit as Yourgene enters the next phase of its growth journey. We look forward to leveraging the team's experience and continuing to build a truly international molecular diagnostics business."
 
Appendix - Appointment of Dr John Robert Brown CBE
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Dr Brown (aged 64):
 



Current appointments


Appointments in the last 5 years




Acacia Pharma Group plc


BBI Diagnostics Group 2 plc




BioCity Nottingham Limited


BioIndustry Association




BioCity Group Limited


CXR Biosciences Limited




Cell Therapy Catapult Limited


Electrical Geodesics Inc.




Craigmhor Consulting Limited


Kyowa Kirin International plc




JWEB Limited


Mode Diagnostics Limited




Mobius Technology Limited


Quantum Pharma plc




Synpromics Limited


Scottish LifeSciences Association








Touch Bionics Limited








Vectura Group plc



 
Dr Brown does not hold any share or options in the Company.
 
There is no further information regarding Dr Brown required to be disclosed under the AIM Rules.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.




 
 



For more information, please contact:
 








Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
investors@yourgene-health.com
 


Tel: +44 (0)161 667 6865
 
 




Cairn Financial Advisers LLP (Nomad)
Liam Murray / James Caithie / Ludovico Lazzaretti
 


Tel: +44 (0)20 7213 0880




Stifel Nicolaus Europe Limited (Sole Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
 


Tel: +44 (0)20 7710 7600




Vigo Communications (PR)
Ben Simons / Fiona Henson / Antonia Pollock
yourgene@vigocomms.com


Tel: +44 (0)20 7390 0238
 



 
 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The Group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOACKFDNBBKDOOB